Renaissance Capital logo

Mangoceuticals Priced, Nasdaq: MGRX

Provides an erectile dysfunction product via telehealth.

Industry: Health Care

Latest Trade: $0.52 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: -87.0%

Industry: Health Care

We plan to connect consumers to licensed healthcare professionals through our recently launched website at www.MangoRX.com for the provision of care via telehealth on our customer portal and plan to also provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. To date, we have developed what we believe is a go-to-market strategy inclusive of product development, operations, marketing and advertising; however, we have not produced a significant amount of products and have generated only nominal revenues to date. We have identified men’s wellness telemedicine services and products as a growing sector in recent years and especially related to the areas of erectile dysfunction (“ED”) products. We have developed and are currently in the process of preparing to commercially market a new brand of ED product under the brand name “Mango.” This product is produced at a compounding pharmacy and is available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Our ED product has not been, and will not be, approved by the FDA.
more less
IPO Data
IPO File Date 01/13/2023
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 1.3
Deal Size ($mm) $5
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/20/2023
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 1.3
Deal Size ($mm) $5
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Boustead Securities
Sutter Securities
Company Data
Headquarters Dallas, TX, United States
Founded 2021
Employees 3
Website www.MangoRX.com

Mangoceuticals (MGRX) Performance